SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-043513
Filing Date
2020-02-20
Accepted
2020-02-20 16:15:43
Documents
14
Period of Report
2020-02-20
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d871008d8k.htm   iXBRL 8-K 28205
2 EX-99.1 d871008dex991.htm EX-99.1 98088
6 GRAPHIC g871008g0220080403336.jpg GRAPHIC 3003
  Complete submission text file 0001193125-20-043513.txt   266936

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA pbyi-20200220.xsd EX-101.SCH 3097
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE pbyi-20200220_lab.xml EX-101.LAB 18139
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE pbyi-20200220_pre.xml EX-101.PRE 11426
9 EXTRACTED XBRL INSTANCE DOCUMENT d871008d8k_htm.xml XML 3369
Mailing Address 10880 WILSHIRE BLVD. SUITE 2150 LOS ANGELES CA 90024
Business Address 10880 WILSHIRE BLVD. SUITE 2150 LOS ANGELES CA 90024 (424) 248-6500
PUMA BIOTECHNOLOGY, INC. (Filer) CIK: 0001401667 (see all company filings)

IRS No.: 770683487 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35703 | Film No.: 20635257
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences